People: Immuron Ltd (IMC.AX)

IMC.AX on Australia Stock Exchange

0.00AUD
17 May 2013
Price Change (% chg)

$0.00 (+33.33%)
Prev Close
$0.00
Open
$0.00
Day's High
$0.00
Day's Low
$0.00
Volume
150,000
Avg. Vol
812,605
52-wk High
$0.02
52-wk Low
$0.00

Search Stocks

Summary

Name Age Since Current Position

Roger Aston

 56 2012 Non-Executive Chairman of the Board

Amos Meltzer

 2013 Interim Chief Executive Officer

Elane Zelcer

 2012 Non-Executive Deputy Chairman of the Board

Grant Rawlin

 2011 Chief Scientific Officer

Gerhard Rank

 Head - Production and Product Management

Mark Sullivan

 Head - Clinical Research Programs

Nina Webster

 Head - Commercialization and Intellectual Property

Phillip Hains

 2013 Joint Company Secretary

Peter Vaughan

 2013 Joint Company Secretary

Daniel Pollock

 2012 Director

Stewart Washer

 2012 Non-Executive Independent Director
» Insider Trading

Biographies

Name Description

Roger Aston

 Dr. Roger Aston, Ph.D., is Non-Executive Chairman of the Board of Immuron Limited since October 8, 2012. He was appointed Non-Executive Director on May 5, 2012. Within the Company he is Member of Audit and Risks Committee. Dr. Aston has more than 20 years of experience in the pharmaceutical and biotech industries. Dr. Aston was previously the Chief Executive Officer and a Director of Mayne Pharma Group Limited. Prior to his position at Mayne Pharma, some of his previous positions have included CEO of Peptech Limited (Australia), Director of Cambridge Antibody Technology Limited (UK) and Chairman of Cambridge Drug Discovery Limited (UK – now Bio Focus plc). Dr. Aston was also founder and CEO of Biokine Technology Ltd (UK) prior to its acquisition by the Peptech Group. Dr. Aston was also a director of pSivida Ltd. During the past 20 years of his career, Dr. Aston has been closely involved in the development of a number of pharmaceutical and biotechnology companies. Dr. Aston has experience including negotiating global license agreements, overseeing product registration activities with the FDA, the establishment and implementation of guidelines and operating procedures for manufacturing and clinical trials, overseeing manufacturing of human and veterinary products, private and public fund raising activities and the introduction of corporate governance procedures. Other current directorships include IDT Limited.

Amos Meltzer

 Mr. Amos Meltzer has been Interim Chief Executive Officer of Immuron Ltd since March 2013. He has played a role in the commercial expansion of a number of biotechnology companies, and brings with him a pharmaceutical partnering and licensing experience required to meet the Company's business objectives.

Elane Zelcer

 Dr. Elane Zelcer, Ph.D., is Non-Executive Deputy Chairman of the Board of Immuron Limited since October 8, 2012. Dr. Zelcer has experience in the Biotechnology sector, including CEO positions with biotech companies and the commercialization company at Monash University, and as Independent Director with the Dairy CRC and Chair of the Victorian State Governments’s Bioeconomy Working Group, a component of the State Government’s Biotechnology Strategy. Dr. Zelcer is currently Executive Director of BioConsult Pty Ltd which focuses on assisting early stage companies in the life sciences sector to develop and commercialize their intellectual property through strategic partnering, capital raising and collaboration. She holds a Bachelor of Science (Hons), Doctorate in Philosophy and Graduate Diploma in Marketing. She is Fellow of the Australian Institute of Company Directors. She is Chairman of the Audit and Risks Committee.

Grant Rawlin

 Dr. Grant Rawlin is Chief Scientific Officer at Immuron Limited since January 17, 2011. He is registered veterinary surgeon and Associate Member of the Australian Pharmaceutical Physicians Association. He is specialist in virology and pathology. Dr. Rawlin brings in epidemiology and risk management policy of infectious diseases in many species, with a particular focus on emergency management of infectious diseases at a national level. These skills were gained while working as the Principal Veterinary Officer with the Commonwealth of Australia. Dr. Rawlin is co-inventor on all Anadis patents lodged after 2002. Dr. Rawlin leads the Anadis science team and manages the Anadis interface with other work groups: University of Melbourne – Microbiology, Monash University, Murdoch Children's Research Institute, Defence Science & Technology Organisation, clinical trial bases, experimental farms and other facilities. Dr. Rawlin has in managing multi-disciplinary technical information to expedite the passage of innovative products through the regulatory process. Dr. Rawlin holds a Bachelor of Science - Veterinary (University of Sydney), and a Bachelor of Veterinary Science (University of Sydney).

Gerhard Rank

Mark Sullivan

Nina Webster

Phillip Hains

 Mr. Phillip Hains is Joint Company Secretary of Immuron Ltd since April 19, 2013. Mr. Hains is a Chartered Accountant and specialist in the public company environment. He services the needs of a number of public company boards and related committees as both their Company Secretary and Chief Financial Officer. He has had over 20 years’ experience in providing accounting, administration, compliance and general management services to both ASX and NASDAQ listed companies.

Peter Vaughan

 Mr. Peter Vaughan is Joint Company Secretary of Immuron Ltd since April 19, 2013. Mr. Vaughan is also a Chartered Accountant who has worked in the listed company environment for 10 years across a number of industries serving various finance roles, including the roles of Company Secretary and Chief Financial Officer.

Daniel Pollock

 Mr. Daniel Pollock is Director of Immuron Ltd since October 11, 2012. He is a lawyer and has commercial experience in new market entries into overseas markets, including USA, as well as cross-national merger and acquisition projects, distribution agreements and corporate start-ups.

Stewart Washer

 Dr. Stewart James Washer, Ph.D., serves as Non-Executive Independent Director of Immuron Ltd since February 7, 2012. He has 20 years of senior executive and Board experience in medical device, drug development and agrifood companies. He was a founder of a New Zealand based life science fund. He is currently the Investment Director with Octa Phillip Bioscience Managers. Dr. Washer was previously the CEO of Calzada Limited, the founding CEO of Phylogica Limited and prior to those two positions he was the CEO of Celentis. Dr. Washer has held a number of Board positions in the past as the Chairman of Resonance Health Limited and Hatchtech Pty Ltd, and as a Director of iCeutica Pty Ltd and AusBiotech Limited. He is currently the Chairman of iSonea Limited and is a former Senator of Murdoch University in Western Australia. He graduated with a Ph.D from Murdoch University.

Basic Compensation

Name Fiscal Year Total

Roger Aston

 --

Amos Meltzer

 246,300

Elane Zelcer

 --

Grant Rawlin

 107,340

Gerhard Rank

 --

Mark Sullivan

 --

Nina Webster

 --

Phillip Hains

 --

Peter Vaughan

 --

Daniel Pollock

 --

Stewart Washer

 --
As Of 29 Jun 2012

Insider Trading

» Full list on Insider Trading
Search Stocks